AVEO PHARMACEUTICALS, INC.
DelistedCIK 1325879fmd_0P6B7CHZXVAE3Z19A00DVZYFZGManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2022, 51 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 19 | 1 | 18 | 19 | 3 | 8 | 5 | 29 | 6 | 42 |
| Cost of revenue | – | – | – | – | – | – | – | 0 | 0 | 5 |
| Gross profit | – | – | – | – | – | – | – | 29 | 6 | 38 |
| Research and development | 91 | 68 | 38 | 13 | 24 | 25 | 21 | 18 | 23 | 26 |
| Selling, general and administrative | – | – | – | – | – | – | 11 | 11 | 22 | 61 |
| Total operating expenses | 131 | 105 | 69 | 31 | 32 | 36 | 31 | 29 | 45 | – |
| Operating income | (112) | (104) | (50) | (12) | (29) | (29) | (25) | (0) | (39) | (50) |
| Interest expense | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | – |
| Interest and investment income | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | (3) | (3) | (2) | (3) | 3 | (36) | 20 | 10 | 3 | (4) |
| Income before taxes | – | – | (53) | (15) | (27) | (65) | (5) | 9 | (36) | – |
| Income tax expense | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | (27) | (65) | (5) | 9 | (36) | – |
| Net income | (114) | (107) | (53) | (15) | (27) | (65) | (5) | 9 | (36) | (53) |
| Net income to common shareholders | (114) | (107) | – | – | (27) | (65) | (5) | 9 | (36) | (53) |